{"id":2612,"date":"2016-07-12T18:11:00","date_gmt":"2016-07-12T18:11:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2612"},"modified":"2025-01-15T20:26:18","modified_gmt":"2025-01-15T20:26:18","slug":"is-elimination-of-hcv-possible-in-a-country-with-low-diagnostic-rate-and-moderate-hcv-prevalence-the-case-of-greece","status":"publish","type":"post","link":"https:\/\/cdafound.org\/es\/is-elimination-of-hcv-possible-in-a-country-with-low-diagnostic-rate-and-moderate-hcv-prevalence-the-case-of-greece\/","title":{"rendered":"\u00bfEs posible la eliminaci\u00f3n del VHC en un pa\u00eds con una tasa de diagn\u00f3stico baja y una prevalencia moderada del VHC ?: El caso de Grecia"},"content":{"rendered":"<h2 class=\"wp-block-heading\">Resumen<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Antecedentes y objetivo<\/h3>\n\n\n\n<p>Se prev\u00e9 que el tratamiento de la hepatitis C (VHC) con antivirales de acci\u00f3n directa (AAD) sin interfer\u00f3n (IFN) cambiar\u00e1 la carga futura de enfermedad. El objetivo de este estudio es cuantificar el impacto de los AAD sin IFN en la morbilidad y la mortalidad relacionadas con el VHC en Grecia en diferentes escenarios relacionados con la cobertura del tratamiento y la prevenci\u00f3n primaria, incluido el propuesto por la Estrategia mundial contra la hepatitis de la Organizaci\u00f3n Mundial de la Salud. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">M\u00e9todos<\/h3>\n\n\n\n<p>Se utiliz\u00f3 un modelo descrito anteriormente para proyectar la carga de morbilidad futura hasta 2030 en escenarios que incluyen el tratamiento basado en la combinaci\u00f3n de IFN pegilado con ribavirina (caso base) y escenarios que utilizan terapias con AAD. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Resultados<\/h3>\n\n\n\n<p>En el escenario del caso base, se prev\u00e9 un aumento de la morbilidad y la mortalidad relacionadas con el VHC en Grecia (mortalidad en 2030: + 23,6% en comparaci\u00f3n con 2015). Si los AAD se utilizan con la misma cobertura de tratamiento, se prev\u00e9 que el n\u00famero de casos de carcinoma hepatocelular y de muertes relacionadas con el h\u00edgado sea menor en 4%-7% en comparaci\u00f3n con 2015. Con una mayor cobertura de tratamiento (de 2000 tratados \/ a\u00f1o a aproximadamente 5000 \/ a\u00f1o en 2015-2020 y 2500 \/ a\u00f1o posteriormente), la morbilidad y la mortalidad disminuir\u00e1n en 43%-53% en 2030 en comparaci\u00f3n con 2015. Para lograr los objetivos de la Estrategia mundial contra la hepatitis de la OMS, un total de 86.500 pacientes con hepatitis C cr\u00f3nica deber\u00e1n ser tratados durante 2016 -2030. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Conclusiones<\/h3>\n\n\n\n<p>La eliminaci\u00f3n del VHC en Grecia para 2030 requiere grandes mejoras en la prevenci\u00f3n primaria, la implementaci\u00f3n de grandes programas de detecci\u00f3n y una alta cobertura de tratamiento.<\/p>\n\n\n\n<p><strong>Pa\u00edses:<\/strong> Grecia<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27403912\" target=\"_blank\" rel=\"noreferrer noopener\">Lea el informe completo<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary Background &amp; Aim The treatment of hepatitis C (HCV) with interferon (IFN)-free Direct-Acting Antivirals (DAAs) is anticipated to change the future burden of disease. Aim of this study is to quantify the impact of IFN-free DAAs on HCV-related morbidity and mortality in Greece under different scenarios concerning treatment coverage and primary prevention, including the [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3322,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[31,10],"publication-author":[797,798,1108,494,1107,796],"class_list":["post-2612","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-elimination","tag-hcv","publication-author-gountas-i","publication-author-hatzakis-a","publication-author-papatheodoridis-g","publication-author-razavi-h","publication-author-souliotis-g","publication-author-sypsa-v"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/comments?post=2612"}],"version-history":[{"count":5,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2612\/revisions"}],"predecessor-version":[{"id":7575,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2612\/revisions\/7575"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media\/3322"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media?parent=2612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/categories?post=2612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/tags?post=2612"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/publication-author?post=2612"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}